{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:49:33Z","timestamp":1790887773129,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,15]]},"DOI":"10.1097\/qai.0b013e3182410503","type":"journal-article","created":{"date-parts":[[2011,11,30]],"date-time":"2011-11-30T11:34:37Z","timestamp":1322652877000},"page":"455-462","source":"Crossref","is-referenced-by-count":77,"title":["Safety, Tolerability, and Pharmacokinetic Interactions of the Antituberculous Agent TMC207 (Bedaquiline) With Efavirenz in Healthy Volunteers"],"prefix":"10.1097","volume":"59","author":[{"given":"Kelly E.","family":"Dooley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Gun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Swindells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoninah","family":"Cramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Aweeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilene","family":"Wiggins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Lizak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Qasba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"van Heeswijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20210131","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1056\/NEJMoa0905848","article-title":". Timing of initiation of antiretroviral drugs during tuberculosis therapy.","volume":"362","author":"Abdool Karim","year":"2010","journal-title":"N Engl J Med"},{"key":"R3-5-20210131","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1056\/NEJMoa1014181","article-title":". Integration of antiretroviral therapy with tuberculosis.","volume":"365","author":"Abdool Karim","year":"2011","journal-title":"N Engl J Med"},{"key":"R4-5-20210131","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa1013911","article-title":". Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.","volume":"365","author":"Blanc","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-5-20210131","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJMoa1013607","article-title":". Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.","volume":"365","author":"Havlir","year":"2011","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"R6-5-20210131","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1086\/518655","article-title":". Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.","volume":"196","author":"McIlleron","year":"2007","journal-title":"J Infect Dis"},{"key":"R7-5-20210131","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1126\/science.1106753","article-title":". A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.","volume":"307","author":"Andries","year":"2005","journal-title":"Science"},{"key":"R8-5-20210131","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.00766-06","article-title":". Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.","volume":"50","author":"Lounis","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"R9-5-20210131","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nchembio884","article-title":". Diarylquinolines target subunit c of mycobacterial ATP synthase.","volume":"3","author":"Koul","year":"2007","journal-title":"Nat Chem Biol"},{"key":"R10-5-20210131","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1128\/AAC.00898-06","article-title":". Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.","volume":"51","author":"Ibrahim","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-5-20210131","doi-asserted-by":"crossref","first-page":"e17556","DOI":"10.1371\/journal.pone.0017556","article-title":". Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis.","volume":"6","author":"Veziris","year":"2011","journal-title":"PLoS One"},{"key":"R12-5-20210131","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1128\/AAC.00978-10","article-title":". Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs.","volume":"55","author":"Shang","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R14-5-20210131","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1056\/NEJMoa0808427","article-title":". The diarylquinoline TMC207 for multidrug-resistant tuberculosis.","volume":"360","author":"Diacon","year":"2009","journal-title":"N Engl J Med"},{"key":"R16-5-20210131","doi-asserted-by":"crossref","first-page":"849","DOI":"10.2217\/fmb.10.50","article-title":". TMC207: the first compound of a new class of potent anti-tuberculosis drugs.","volume":"5","author":"Matteelli","year":"2010","journal-title":"Future Microbiol"},{"key":"R18-5-20210131","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1086\/597125","article-title":". Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African Americans.","volume":"199","author":"Haas","year":"2009","journal-title":"J Infect Dis"},{"key":"R19-5-20210131","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1086\/605126","article-title":". CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.","volume":"200","author":"Leger","year":"2009","journal-title":"J Infect Dis"},{"key":"R21-5-20210131","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1086\/589867","article-title":". Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.","volume":"47","author":"Hare","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R26-5-20210131","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1128\/AAC.00934-10","article-title":"Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis.","volume":"54","author":"Andries","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-5-20210131","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1128\/AAC.01204-07","article-title":". Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis.","volume":"52","author":"Rustomjee","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R28-5-20210131","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions.","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"R29-5-20210131","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic amphiphilic drug-induced phospholipidosis.","volume":"25","author":"Halliwell","year":"1997","journal-title":"Toxicol Pathol"},{"key":"R32-5-20210131","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1128\/AAC.01120-08","article-title":". Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine.","volume":"53","author":"Zhu","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R34-5-20210131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mcp.2002.124519","article-title":". Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.","volume":"72","author":"Mouly","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"R35-5-20210131","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1128\/AAC.00566-08","article-title":". Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.","volume":"52","author":"Lounis","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R36-5-20210131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.106.112136","article-title":". Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.","volume":"320","author":"Faucette","year":"2007","journal-title":"J Pharmacol Exp Ther"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0b013e3182410503","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:54:33Z","timestamp":1620971673000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201204150-00005"}},"subtitle":["AIDS Clinical Trials Group Study A5267"],"short-title":[],"issued":{"date-parts":[[2012,4,15]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e3182410503","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4,15]]}}}